Relay Therapeutics, Inc.
RLAY
Helyezés a részvények között
#4010
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Részvényárfolyam
$18.65
Utolsó szinkronizálás: 2026-10-20
Piaci kapitalizáció
$4.09B
Változás (1 nap)
9.15%
Változás (1 év)
164.96%
Ország
US
Kereskedés Relay Therapeutics, Inc. (RLAY)
Kategória
Healthcare
Relay Therapeutics, Inc. (RLAY) P/B aránya
P/B arány ekkor: October 2026 TTM: 3.89
Relay Therapeutics, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 3.89. 2023 végén ez az arány 1.79 volt.
P/B arány története a(z) Relay Therapeutics, Inc. esetén 2018 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 3.89 | 411.62% |
| 2024 | 0.76 | -57.83% |
| 2023 | 1.79 | 1.70% |
| 2022 | 1.76 | -45.77% |
| 2021 | 3.25 | -33.63% |
| 2020 | 4.90 | -689.61% |
| 2019 | -0.83 | 5.91% |
| 2018 | -0.79 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | 60.76% |
US
|
|
| 13.2547 | 240.89% |
US
|
|
| 4.208 | 8.22% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 59.00% |
NL
|
